



Name: DoB:

Hospital number:

CHI:

## Multi Disciplinary Care Pathway for

## PARACETAMOL OVERDOSE

Ingested over a period of one hour or less - presenting more than 24 hours after acute ingestion

This care pathway includes the <u>ADULT</u> SNAP based regimen for acetylcysteine and is **ONLY** for use in <u>NHS LOTHIAN</u>

For advice contact the on-call toxicologist at the RIE (Monday – Friday 8.30 am – 6 pm) or the National Poisons information Service Tel 0344 892 0111 (out of hours)

Multi Disciplinary Care Pathway for	Patient Label, or
PARACETAMOL OVERDOSE – More than 24 HOURS	Name:
Date:	DoB:
Hospital: RIE □ SJH □ WGH □	Hospital number:
Clinical area: ED/A&E □ AMU □ MAU □ Obs Ward □	CHI:
	NHS Lothian

To be initiated once a PARACETAMOL overdose is suspected Ingested over a period of one hour or less - presenting more than 24 hours after acute ingestion

KEY TO INITIALS OF <u>ALL</u> STAFF COMPLETING THIS CARE PATHWAY					
Print name	Designation	Initials	Signature	Date	
1					
2					
3					
4					
5					
6					

**PATIENT:** This document is a supplement to your record of treatment for an admission with a

suspected or confirmed paracetamol overdose.

Should be completed in addition to the Inpatient Record (nursing admission, medical clerking, Toxicology Questionnaire), NEWS observation chart, ED shock chart, Infusion charts and Prescription & Administration Record.

SUMMARY			Initials & time
Ingestion date	Was para	acetamol bought for overdose: Yes	No □
List all the drug(s) ingested		acetamol ingestedweight	· ·
	CALCUL The amo	ATE unt of paracetamol ingested	mg / kg
	Notes	For obese patients weighing more than toxic dose in mg/kg should be calculated unather than the patient's actual weight.  For pregnant patients the toxic dose in more be calculated using the patient's pre pregnant patient	using 110kg, ng/kg should
Alcohol ingested? Yes □ No □	There is	a dosage calculator on TOXBASE® for calc	ulating mg/kg.

This document represents the care expected for a majority of your patients. It is to be expected that some patients will need care other than that noted. This is referred to as a 'Variance' and should be noted as 'Var' in the appropriate space & explained fully on the 'Variance' sheet, page 8.

Clinicians are free to exercise their own professional judgements as appropriate. However, any alteration to practice noted in this document should be noted as a 'Variance' in notes.

Please tick boxes as appropriate and initial / time in conjunction with the Inpatient record.

Multi Disciplinary Care Pathway for	Patient Label, or
PARACETAMOL OVERDOSE – More than 24 HOURS  Date:	Name: DoB:
Hospital: RIE □ SJH □ WGH □	Hospital number:
Clinical area: ED/A&E □ AMU □ MAU □ Obs Ward □	CHI:
	NHS Lothian
Ingested over a period of one hour or less - presenting mor	re than 24 hours after acute ingestion
Give acetylcysteine <b>immediately</b> to all patients if it is thought that 150 ingested as an acute overdose (i.e. all doses taken within one hour) of hepatic tenderness.	
If the patient is asymptomatic and has ingested less than 150 mg/kg, vertical treatment with acetylcysteine.	wait for blood results before considering
STAGE 1 - IMMEDIATE ASSESSMENT AN	ID MANAGEMENT
Assessment Thought to have taken 150 mg/kg or more <b>OR</b> clinical features of h	epatic injury Yes □ No □
If Yes,     START ACETYLCYSTEINE IMMEDIATELY DO NOT WAIT FO     (Refer to SNAP based dosage table on Page 5)	OR BLOOD RESULTS
<ul><li>If no,</li><li>Wait for bloods results to determine if acetylcysteine is required</li></ul>	
Blood sampling     Obtain urgent blood samples for paracetamol concentration, glucose, FBC, INR	U&Es, TCO <sub>2</sub> , LFTs,
ON RECEIPT OF BLOOD RESULTS:	Initial & time
Date, time and blood results documented on page 4	
If treatment has not been initiated START acetylcysteine if:	
Paracetamol concentration is detectable (5 mg/L or more) OR	
INR is greater than 1.3 (in the absence of another cause, e.g. warf	farin) <b>OR</b>
ALT is above the upper limit of normal (50 U/L)	
Patients with a chronically elevated ALT (e.g. chronic liver dise treatment if the ALT and INR have not significantly changed fr cases should be discussed with the National Poisons Informat Haemodialysis may be indicated alongside acetylcysteine if the	om previously documented values. These tion Service (NPIS) Tel 0344 892 0111
concentration and an elevated lactate. For advice contact loca	al toxicologist or NPIS out of hours
The patient is considered not to be at risk of liver toxicity if:	Initial & time
Paracetamol concentration is not detectable (less than 5 mg/L) AN	ND .
• INR is 1.3 or less AND	
ALT is within normal range (50 U/L or less) AND  The section of the section	
<ul> <li>The patient is asymptomatic with no clinical features suggesting liver.</li> </ul>	ver damage
If these criteria are met the acetylcysteine if not required	
If these criteria are met and acetylcysteine has been started it can	be discontinued
Assessment of renal function	tiont can be discharged
<ul> <li>If acetycysteine is not required and the creatinine is normal the patent Provide the patient with a 'Patient Information Sheet' (available or</li> </ul>	
<ul> <li>If acetylcysteine is not required and the creatinine is abnormal the hospital for monitoring of renal function and if required, treated cor</li> </ul>	patient should remain in
If treatment with acetylcysteine is not indicated and further	

Multi Disciplinary Care Pathway for	Patient Label, or
PARACETAMOL OVERDOSE – More than 24 HOURS	Name:
Date:	DoB:
Hospital: RIE □ SJH □ WGH □	Hospital number:
Clinical area: ED/A&E □ AMU □ MAU □ Obs Ward □	CHI:

NHS Lothian

If you complete an entry on this page, initial as you complete each aspect of care then complete the 'KEY TO INITIALS' table on page 1 sign/print/designation.

Assessment blood results Date/Time of sample	Repeat blood results (if required) Date/Time of sample
Urea	Urea
Sodium	Sodium
Potassium	Potassium
TCO <sub>2</sub>	TCO <sub>2</sub>
Creatinine	Creatinine
eGFR	eGFR
Bilirubin	Bilirubin
ALT	ALT
Alk Phos	Alk Phos
Hb	Hb
MCV	MCV
WCC	WCC
Platelets	Platelets
INR	INR
Plasma paracetamol concentration	Plasma paracetamol concentration athours post ingestion
Glucose	Glucose
H+	H+
Lactate	Lactate
HCO₃	HCO₃
TCO <sub>2</sub>	TCO <sub>2</sub>
Other	Other
Initials date / time	Initials date / time

ARA( ate: ospital	ulti Disciplinary Care Pathway for ARACETAMOL OVERDOSE – More than 24 HOURS ate:  pspital: RIE   SJH   WGH   Inical area: ED/A&E   AMU   MAU   Obs Ward				Patient Label, o	or NHS Lothian	
	STAGE 2 -	· INITIATION OF	TREATMENT	WITH ACETYLO	YSTEINE		
	Calculate acety	OR OBESE PATIE vlcysteine dose us FOR P acetylcysteine dos	ing 110 kg rather <b>REGNANT PATII</b>	than the patient's <b>ENTS</b>	actual weight		
	THIS SI	THIS SNAP BASED DOSAGE TABLE IS ONLY FOR USE IN  NHS LOTHIAN  Adult acetylcysteine prescription  (each ampoule = 200 mg/mL acetylcysteine)					
	Regimen	First Inf	fusion	Second In	fusion	-	
	Infusion fluid	200 mL 5% <u>ք</u>	glucose <sup>1</sup> or	1000 mL 5% <u>ք</u>	1000 mL 5% glucose <sup>1</sup> or		
		sodium chlo	oride 0.9%	sodium chlo	sodium chloride 0.9%		
	Duration of infusion	2 ho			10 hours		
	Drug dose	100 mg/kg ac Ampoule volume <sup>3</sup>	etylcysteine Infusion Rate	200 mg/kg ace Ampoule volume <sup>3</sup>	200 mg/kg acetylcysteine		
	Patient Weight <sup>2</sup>	mL	mL/h	mL	Infusion Rate mL/h	-	
	kg 30-39		•		•	-	
	40-49	18	109	35	104		
	50-59	23	112	45	105	_	
	60-69	28	114	55	106	-	
	70-79	33	117	65	107	-	
	80-89	38	119	75	108		
	90-99	43	122	85	109	-	
	100-109	48 53	124 127	95 105	110 111	1	
	≥110	55	128	110	111	-	
	<sup>1</sup> Check capillary blood glud <sup>2</sup> Dose calculations are bas <sup>3</sup> Ampoule volume has bee	Lcose at least once in alled on the weight in the	I patients, and 4-hourle middle of each band	y in patients with diabe			

Patient's weight ..... kg Prescription and Administration record completed Date/time treatment commenced Initial

REACTION to acetylcysteine			COMPLICATIONS of paracetamol ingestion				
None		Wheeze		Abnormal liver function		Encephalopathy	
Flushing		Hypotension		Acute kidney injury		Haemorrhage	
Vomiting		Other		Hypoglycaemia		Other	
Rash/Itch		Specify		Acidosis		Specify	
Date and time of reaction		Initial		Date and time of compli	catior	n Initia	

Multi Disciplinary Care Pathway for	Patient Label, or
PARACETAMOL OVERDOSE – More than 24 HOURS	Name:
Date:	DoB:
nospital. Rie 🗆 33n 🗀 WGn 🗀	Hospital number:
Clinical area: ED/A&E □ AMU □ MAU □ Obs Ward □	CHI:
	NHS Lothian

STAGE 3 – END OF TREATMENT WITH ACETYLCYSTEINE	
• End bag 2 blood samples U&Es, TCO2, LFTs, FBC, INR & PARACETAMOL CONCENTRATION	
End of bag 2 blood results - documented in table below	Initial & time

	Blood results				
	Admission Bloods	End of bag 2 bloods	End of extended bag 1 bloods	End of extended bag 2 bloods	End of extended bag 3 bloods
Notes	* Copy from page 4	Obtain blood samples at the end of bag 2	Obtain blood samples at the end of extended bag 1	Obtain blood samples at the end of extended bag 2	Obtain blood samples at the end of extended bag 3
		Date/time taken	Date/time taken	Date/time taken	Date/time taken
		Initial	Initial	Initial	Initial
Urea					
Sodium					
Potassium	*				
TCO <sub>2</sub>					
Creatinine	*				
eGFR					
Bilirubin					
ALT	*				
Alk. Phos					
Hb					
WCC					
Platelets					
INR	*				
Paracetamol	*				
Reviewed by		Initial	Initial	Initial	Initial
Decision		Continue / stop	Continue / stop	Continue / stop	Continue / stop

## **END OF BAG 2 bloods review:**

• Criteria for DISCONTINUING acetylcysteine after Bag 2 are:

ALT is less than 50 U/L AND

ALT is less than double the admission measurement (even within normal range) AND

PARACETAMOL concentration is less than 10 mg/L

• If criteria are NOT met continue with extended acetylcysteine

\*Patients with isolated INR rise of less than 0.5

For patients who have an isolated INR rise of less than 0.5, stop acetylcysteine and recheck INR and ALT after 4-6 hours.

• Criteria for DISCONTINUING acetylcysteine at this point are:

INR is unchanged or falling AND

ALT is less than 50 U/L

• If criteria not met – restart acetylcysteine at the dose and infusion rate of the last treatment bag.

Multi Disciplinary Care Pathway for Patient Label, or				
PARACETAMOL OVERDOSE – More than 24 HOURS Date:	Name: DoB:			
Hospital: RIE □ SJH □ WGH □	Hospital number:			
Clinical area: ED/A&E □ AMU □ MAU □ Obs Ward □	CHI:			
	NH	lS Lo	othian	
If creatinine is abnormal or is 10% greater than at presentation, further ace	tyloveteine is not required but renal ful	nction		
should be monitored as an inpatient. Re-check 12 hours later.	tyloysteine is not required but remaind	ictioi		
<ul> <li>End of bag 2 blood results reviewed by medical staff (of grade FY2 and above)</li> <li>Decision to discontinue or continue acetylcysteine documented in the table above and on page 7</li> </ul>				
STAGE 3 – END OF TREATMENT WITH	ACETYLCYSTEINE			
If criteria for discontinuing acetylcysteine at end of Bag 2	are met:		Initial	
Discontinue acetylcysteine. Time infusion discontinued				
<ul> <li>Decision</li> <li>If further treatment or blood sampling is not required go to Sta Management &amp; Discharge'(page 8)</li> </ul>	age 4 'Subsequent		Initial & time	
<ul> <li>If monitoring of renal function is required obtain blood sample a medical review</li> </ul>	es 12 hours later followed by			
If extended acetylcysteine is indicated follow advice below				
If criteria for discontinuing acetylcysteine at the end of Ba	a 2 are NOT mot:		Initial	
			& time	
<ul> <li>Continue extended acetylcysteine treatment at the dose and</li> <li>Obtain blood samples for U&amp;Es, TCO<sub>2</sub>, LFTs, FBC &amp; INR at t</li> </ul>	• " • ,			
Extended bag 1 bloods due at obtained at	<u> </u>	_		
<ul> <li>End of Extended bag 1 bloods review:</li> <li>Criteria for DISCONTINUING acetylcysteine after extended bag</li> </ul>	1 aro			
INR is 1.3 or less and has not risen by 0.5 or more from adr				
ALT is less than two times the upper limit of normal (less that				
ALT is less than double the admission measurement				
If the criteria for discontinuing are NOT met continue with furth				
If creatinine is abnormal or is 10% greater than at presentation, further function should be monitored as an inpatient. Re-check 12 hours later		t ren	al	
*Patients with isolated INR rise of less than 0.5	deveteine en develople IND en d A	T -4	A	
For patients who have an isolated INR rise of less than 0.5, stop acet 6 hours.	yicysteine and recheck link and A	LIai	ter 4-	
Criteria for DISCONTINUING acetylcysteine at this point are:  INR is unchanged or falling AND				
ALT is less than two times the upper limit of normal (less than	n 100 U/L)			
Otherwise commence 2 <sup>nd</sup> extended bag of acetylcysteine	,			
<ul> <li>End of extended bag 1 blood results reviewed by medical st</li> <li>Decision to discontinue or continue acetylcysteine document and in the decision box below</li> </ul>	· •		Initial & time	
<ul><li>Decision</li><li>If further treatment or blood sampling is not required go to Stage</li></ul>	4 'Subsequent Management &		Initial & time	
Discharge'(page 8)  If repal function monitoring is required obtain samples 12 hours leads to the control of th	ater followed by medical review			
<ul> <li>If renal function monitoring is required obtain samples 12 hours later followed by medical review</li> <li>If further extended acetylcysteine is indicated follow advice below</li> </ul>				

Multi Disciplinary Care Pathway for	Patient Label, or				
PARACETAMOL OVERDOSE – More than 24 HOURS	Name:				
Date:	DoB:				
Hospital: RIE □ SJH □ WGH □	Hospital number: CHI:				
Clinical area: ED/A&E □ AMU □ MAU □ Obs Ward □	CHI:				
NHS Lot					
If further extended treatment is required	• •				Initial & time
Continue acetylcysteine at the dose and infusion rate used in the 2 <sup>nd</sup> treatment bag (Page 5)					1
• Ward level capillary blood glucose monitoring (BMs) at least four	capillary blood glucose monitoring (BMs) at least four times daily				l
<ul> <li>Recheck U&amp;Es, LFTs, FBC and INR every 9 hours to assess the before the end of each extended bag). Document results on page</li> </ul>	eck U&Es, LFTs, FBC and INR every 9 hours to assess the course of liver injury (1 hour et the end of each extended bag). Document results on page 6				1
Discontinue further extended treatment when:					
<ul> <li>INR 1.3 or less; OR falling towards normal on two consecutive blood tests, <u>and</u> less than 3.</li> <li>There is no clinical advantage to treating ALT rises after this normalisation in INR (indicating restoration of hepatic synthetic function)</li> </ul>					
Extended treatment with acetylcysteine was required If YES, number of extended bags required	Yes □ N			No 🗆	Initial & time
Once treatment with acetylcysteine is discontinued and further blood tests are not required go to Stage 4 'Subsequent Management & Discharge' (page 8)					
STAGE 4 - SUBSEQUENT MANAGEMENT & DISCHARGE					
					Initial/time
Target Treatment with acetylcysteine tolerated	N/A □	Yes □	No		
Patient eating and drinking.	. 47.1	Yes □	No		
<ul> <li>Seen by Psychiatry team member</li> </ul>	N/A □	Yes □	No		
Comment					
Discharge					Initial/time
Treatment complete	N/A □	Yes □	No		
Criteria for discharge met		Yes □	No		
Comment					
<ul> <li>Discharge advice given, including paracetamol patient dis</li> </ul>	charge sheet				
(available on TOXBASE®)					
NOK informed     Comment		Yes □	No 		
Left department DateTime					
					Initial/time
Follow-up	NI/A 🖂	Vec 🗆	Nic		
<ul> <li>Has follow-up been arranged?</li> </ul>	N/A □	Yes □	No		
Comment					
tes Medical follow-up arrangements are not normally required if blood results are within acceptable re					ange